Citius Pharmaceuticals Reports Fiscal Q3 2026 Financials

Citius Pharmaceuticals, Inc. has reported its financial results for the third quarter of fiscal year 2026 and provided a business update. The company generated $7.1 million in revenue during the first nine months of fiscal 2026, primarily from the commercial sales of its product, LYMPHIR®.

As of June 30, 2026, Citius Pharmaceuticals held $17 million in cash and cash equivalents. This financial position provides the company with liquidity to support its ongoing operations and strategic initiatives.

The company has also expanded its commercial and medical affairs organizations for LYMPHIR, deploying new teams nationwide. This expansion aims to bolster the product's market presence and enhance medical communication efforts.

Citius Pharmaceuticals' strategy remains focused on supporting the commercial launch and adoption of LYMPHIR. The enlarged organizational structure is intended to increase product accessibility and support its utilization within patient care settings.